E ndocrine therapy with accelerated P artial breast irradiati O n or exclusive ultra-accelerated P artial breast irradiation for women aged ≥ 60 years with E arly-stage breast cancer (EPOPE): The rationale for a GEC-ESTRO randomized phase III-controlled trial

Jean-Michel Hannoun-Levi; Emmanuel Chamorey; Rabia Boulahssass; Csaba Polgar; Vratislav Strnad; Breast Cancer Working Group of the GEC-ESTRO

doi:10.1016/j.ctro.2021.04.005

E ndocrine therapy with accelerated P artial breast irradiati O n or exclusive ultra-accelerated P artial breast irradiation for women aged ≥ 60 years with E arly-stage breast cancer (EPOPE): The rationale for a GEC-ESTRO randomized phase III-controlled trial

Clin Transl Radiat Oncol. 2021 Apr 22:29:1-8. doi: 10.1016/j.ctro.2021.04.005. eCollection 2021 Jul.

Authors

Jean-Michel Hannoun-Levi¹, Emmanuel Chamorey², Rabia Boulahssass³, Csaba Polgar⁴, Vratislav Strnad⁵; Breast Cancer Working Group of the GEC-ESTRO

Affiliations

¹ Department of Radiation Oncology, Antoine Lacassagne Cancer Centre, University of Côte d'Azur, Nice, France.
² Department of Epidemiology and Biostatistics, Antoine Lacassagne Cancer Centre, University of Cote d'Azur, Nice, France.
³ Geriatric Unit. CHU de NICE, FHU ONCOAGE, University of Cote d'Azur, Nice, France.
⁴ Department of Oncology, Semmelweis University, Budapest, Hungary.
⁵ Department of Radiation Oncology, Erlangen University Hospital, Erlangen, Germany.

Abstract

Purpose: Breast cancer in the elderly has become a public health concern; there is a need to re-design its treatment with a view to de-escalation. Our paper sets out the rationale for a phase 3 randomized trial to evaluate less burdensome adjuvant procedures that remain effective and efficient.

Materials and methods: For low-risk breast cancer in the elderly, adjuvant treatment has been adjusted in order to make it more suitable and efficient. Hypofractionated radiation therapy based on accelerated or non-accelerated regimens as well as accelerated and ultra-accelerated partial breast irradiation (APBI) protocols were reviewed. Withdrawal of radiation (RT) or endocrine therapies (ET) from the adjuvant procedure were also investigated. Based on molecular and APBI classifications, inclusion criteria were discussed.

Results: Phase 3 randomized trials which compared standard vs. accelerated/non-accelerated hypofractionated regimens confirmed that the latter were non-inferior in terms of local control. Similarly, except for intraoperative-based techniques, APBI achieved non-inferior local control rates compared to whole breast irradiation for low-risk breast cancer. In phase 2 prospective trials using ultra APBI, encouraging results were observed regarding oncological outcome and toxicity profile. In phase 3 trials, adjuvant ET without RT significantly increased the rate of local relapse with no impact on overall survival while RT alone proved effective. Elderly patients aged 60 or more with low-risk, luminal A breast cancer were chosen as the target population in a phase 3 randomized trial comparing APBI + 5-year ET vs. uAPBI (16 Gy 1f) alone.

Conclusion: To investigate de-escalation adjuvant treatment for elderly breast cancer patients, we have defined a road map for testing more convenient strategies. This EPOPE phase 3 randomized trial is supported by the GEC-ESTRO breast cancer working group.

Keywords: ABS, American Brachytherapy Society; APBI, Accelerated and partial breast irradiation; ASTRO, American Society of Radiation Oncology; BCS, Breast cancer surgery; BCWG, Breast Cancer Working Group; Brachytherapy; Breast cancer in the elderly; DCIS, Ductal carcinoma in situ; DFS, Disease-free survival; EPOPE, Endocrine therapy with accelerated Partial breast irradiatiOn or exclusive ultra-accelerated Partial breast irradiation for women aged ≥ 60 years with Early stage breast cancer; EQD2, Equivalent Dose in 2Gy fractions; ET, Endocrine therapy; Endocrine therapy; GEC-ESTRO, Groupe Européen de Curiethérapie/European Society for Therapeutic Radiation and Oncology; HDB, High-dose rate Brachytherapy; LCIS, Lobular carcinoma in situ; MAPBI, Molecular and APBI GEC-ESTRO; MIB, Multicatheter Interstitial Brachytherapy; Oncogeriatric assessment; QoL, Quality of Life; RT, Radiotherapy; Radiation therapy; WBI, Whole breast irradiation; uAPBI, ultra-Accelerated Partial Breast Irradiation.